Bristol Myers Squibb has extended 340B contract pharmacy restrictions to all grantees, which affects health centers. They will recognize up to three contract pharmacies (one for Non-IMids, a second for IMiDs, and a third for Camzyos) for each covered entity. Furthermore, Merck, Teva, and Astellas have lifted 340B drug restrictions for all covered entities in Arkansas and Louisiana. Please note that these restrictions still apply to covered entities in other states. NACHC will continue to update their manufacturer restrictions chart as needed.
